TuHURA Biosciences (HURA) Competitors $3.87 -0.07 (-1.78%) Closing price 04/10/2025 04:00 PM EasternExtended Trading$3.78 -0.10 (-2.45%) As of 04/10/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock HURA vs. PRAX, OCS, CDXC, NUVB, ABCL, CVAC, XNCR, PRTA, REPL, and ABUSShould you be buying TuHURA Biosciences stock or one of its competitors? The main competitors of TuHURA Biosciences include Praxis Precision Medicines (PRAX), Oculis (OCS), ChromaDex (CDXC), Nuvation Bio (NUVB), AbCellera Biologics (ABCL), CureVac (CVAC), Xencor (XNCR), Prothena (PRTA), Replimune Group (REPL), and Arbutus Biopharma (ABUS). These companies are all part of the "pharmaceutical products" industry. TuHURA Biosciences vs. Praxis Precision Medicines Oculis ChromaDex Nuvation Bio AbCellera Biologics CureVac Xencor Prothena Replimune Group Arbutus Biopharma TuHURA Biosciences (NASDAQ:HURA) and Praxis Precision Medicines (NASDAQ:PRAX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, community ranking, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability. Do institutionals & insiders hold more shares of HURA or PRAX? 0.6% of TuHURA Biosciences shares are held by institutional investors. Comparatively, 67.8% of Praxis Precision Medicines shares are held by institutional investors. 0.2% of TuHURA Biosciences shares are held by company insiders. Comparatively, 2.7% of Praxis Precision Medicines shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media refer more to HURA or PRAX? In the previous week, TuHURA Biosciences had 6 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 16 mentions for TuHURA Biosciences and 10 mentions for Praxis Precision Medicines. Praxis Precision Medicines' average media sentiment score of 0.78 beat TuHURA Biosciences' score of 0.51 indicating that Praxis Precision Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TuHURA Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Praxis Precision Medicines 3 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Do analysts prefer HURA or PRAX? TuHURA Biosciences currently has a consensus target price of $12.67, suggesting a potential upside of 227.30%. Praxis Precision Medicines has a consensus target price of $123.33, suggesting a potential upside of 333.20%. Given Praxis Precision Medicines' higher possible upside, analysts plainly believe Praxis Precision Medicines is more favorable than TuHURA Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TuHURA Biosciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Praxis Precision Medicines 1 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.78 Does the MarketBeat Community believe in HURA or PRAX? Praxis Precision Medicines received 46 more outperform votes than TuHURA Biosciences when rated by MarketBeat users. However, 100.00% of users gave TuHURA Biosciences an outperform vote while only 74.63% of users gave Praxis Precision Medicines an outperform vote. CompanyUnderperformOutperformTuHURA BiosciencesOutperform Votes4100.00% Underperform VotesNo VotesPraxis Precision MedicinesOutperform Votes5074.63% Underperform Votes1725.37% Which has higher valuation and earnings, HURA or PRAX? TuHURA Biosciences has higher earnings, but lower revenue than Praxis Precision Medicines. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTuHURA BiosciencesN/AN/A-$8.32MN/AN/APraxis Precision Medicines$8.55M67.12-$123.28M-$10.27-2.77 Which has more volatility and risk, HURA or PRAX? TuHURA Biosciences has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500. Comparatively, Praxis Precision Medicines has a beta of 2.66, indicating that its stock price is 166% more volatile than the S&P 500. Is HURA or PRAX more profitable? TuHURA Biosciences has a net margin of 0.00% compared to Praxis Precision Medicines' net margin of -9,409.22%. TuHURA Biosciences' return on equity of 0.00% beat Praxis Precision Medicines' return on equity.Company Net Margins Return on Equity Return on Assets TuHURA BiosciencesN/A N/A -152.88% Praxis Precision Medicines -9,409.22%-54.86%-50.52% SummaryPraxis Precision Medicines beats TuHURA Biosciences on 9 of the 16 factors compared between the two stocks. Remove Ads Get TuHURA Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for HURA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HURA vs. The Competition Export to ExcelMetricTuHURA BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$169.04M$6.09B$5.17B$7.38BDividend YieldN/A3.02%5.35%4.25%P/E RatioN/A6.5021.7617.54Price / SalesN/A203.67351.7989.68Price / CashN/A65.6738.1534.64Price / Book-0.945.456.163.81Net Income-$8.32M$141.10M$3.19B$247.05M7 Day Performance13.82%-3.35%-3.87%-3.50%1 Month Performance105.85%-13.17%-2.66%-8.42%1 Year PerformanceN/A-19.80%3.36%-6.46% TuHURA Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HURATuHURA BiosciencesN/A$3.87-1.8%$12.67+227.3%N/A$169.04MN/A0.00N/APositive NewsGap DownPRAXPraxis Precision Medicines2.0682 of 5 stars$31.53-3.4%$123.33+291.2%-43.7%$635.74M$8.55M-3.06110Analyst ForecastNews CoverageGap DownOCSOculis1.8637 of 5 stars$14.37-7.3%$29.50+105.3%+38.3%$627.42M$980,000.00-7.452News CoverageHigh Trading VolumeCDXCChromaDex3.8165 of 5 starsN/A$9.03+∞N/A$611.50M$99.60M787.29120NUVBNuvation Bio2.5026 of 5 stars$1.81+8.7%$8.75+384.8%-42.6%$611.32M$7.87M-0.8360Insider TradeNews CoveragePositive NewsGap DownHigh Trading VolumeABCLAbCellera Biologics1.9375 of 5 stars$2.05-1.9%$7.00+241.5%-53.6%$610.88M$28.83M-3.36500News CoverageGap DownHigh Trading VolumeCVACCureVac3.5118 of 5 stars$2.65+2.3%$10.00+277.4%-3.1%$593.28M$543.28M4.82880News CoverageGap DownXNCRXencor3.5482 of 5 stars$8.37-3.7%$34.38+310.7%-60.9%$589.77M$110.49M-2.62280News CoverageGap DownPRTAProthena3.3553 of 5 stars$10.84-0.2%$55.00+407.4%-57.5%$583.49M$135.16M-4.71130News CoverageGap DownHigh Trading VolumeREPLReplimune Group3.5706 of 5 stars$7.49+0.4%$19.43+159.4%-0.6%$576.84MN/A-2.44210News CoveragePositive NewsABUSArbutus Biopharma1.6096 of 5 stars$3.01-6.8%$5.50+82.7%+4.7%$576.36M$6.17M-7.0090Gap Down Remove Ads Related Companies and Tools Related Companies PRAX Competitors OCS Competitors CDXC Competitors NUVB Competitors ABCL Competitors CVAC Competitors XNCR Competitors PRTA Competitors REPL Competitors ABUS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HURA) was last updated on 4/11/2025 by MarketBeat.com Staff From Our PartnersTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredAll Signs Point To Collapse - 401(k)s/IRAs /Are DoomedRetiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road AheadAmerican Hartford Gold | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TuHURA Biosciences Please log in to your account or sign up in order to add this asset to your watchlist. Share TuHURA Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
